SecProbe.io

CORRESP
 1
 filename1.htm

 GRACE THERAPEUTICS, INC.
 103 Carnegie Center, Suite 300
 Princeton, New Jersey 08540

 March 12, 2025

 VIA EDGAR

 Office of Life Sciences
 Division of Corporation Finance
 U.S. Securities and Exchange Commission
 100 F Street, N.E.
 Washington, D.C. 20549
 Attention: Jason Drory

 Re:
 Grace Therapeutics, Inc.

 Registration Statement on Form S-3

 Filed March 10, 2025

 File No. 333-285661

 Request for Acceleration of Effective Date

 To Whom it May Concern,

 Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Grace Therapeutics, Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date
 of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on March 13, 2025, or as soon thereafter as possible.

 Please direct any questions or comments concerning this request to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671. Also, please notify Mr. Abrams when this request for acceleration has been granted.

 Very truly yours,

 GRACE THERAPEUTICS, INC.

 By:

 /s/ Prashant Kohli

 Name:

 Prashant Kohli

 Title:

 Chief Executive Officer

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 11, 2025

Prashant Kohli
Chief Executive Officer
Grace Therapeutics, Inc.
103 Carnegie Center, Suite 300
Princeton, NJ 08540

 Re: Grace Therapeutics, Inc.
 Registration Statement on Form S-3
 Filed March 10, 2025
 File No. 333-285661
Dear Prashant Kohli:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Steve Abrams
</TEXT>
</DOCUMENT>

CORRESP
1
filename1.htm

    July 31, 2024

    CORRESPONDENCE FILED VIA EDGAR

    Office of Life Sciences

    Division of Corporation Finance

    U.S. Securities and Exchange Commission

    100 F Street, N.E.

    Washington, D.C. 20549

    Attention: Daniel Crawford

            Re:

            Acasti Pharma Inc.

              Registration Statement on Form S-4 (File No. 333-280536)

              Request for Acceleration of Effective Date

    Dear Mr. Crawford:

    Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Acasti Pharma Inc. (the “Company”) hereby respectfully
      requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration Statement on Form S-4 (the “Registration Statement”) and declare the
      Registration Statement effective as of 4:00 p.m. Eastern Time on August 2, 2024, or as soon thereafter as practicable.

    The Company requests that it be notified of such effectiveness by a telephone call to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671.

    [Signature page follows]

            Sincerely,

            Acasti Pharma Inc.

            /s/ Prashant Kohli

            Prashant Kohli

            Chief Executive Officer and Director

July 3, 2024
Prashant Kohli
Chief Executive Officer
Acasti Pharma Inc.
103 Carnegie Center, Suite 300
Princeton, NJ 08540
Re:Acasti Pharma Inc.
Registration Statement on Form S-4
Filed June 27, 2024
File No. 333-280536
Dear Prashant Kohli:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Steven Abrams, Esq.

CORRESP
1
filename1.htm

  CORRESP

  ACASTI PHARMA INC.

  2572 boul. Daniel-Johnson. 2nd Floor

  Laval, Québec, Canada H7T 2R3

  October 12, 2023

  VIA EDGAR

  Office of Life Sciences

  Division of Corporation Finance

  U.S. Securities and Exchange Commission

  100 F Street, N.E.

  Washington, D.C. 20549

  Attn: Joshua Gorsky

  Re:	Acasti Pharma Inc.

  	Registration Statement on Form S-3

  	Filed October 6, 2023

  	File No. 333-274899

  	Request for Acceleration of Effective Date

  Dear Mr. Gorsky:

  	Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Acasti Pharma Inc. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on October 16, 2023, or as soon thereafter as possible.

  	Please direct any questions or comments concerning this request to Brandon Kinnard of Hogan Lovells US LLP at (303) 454-2477. Also, please notify Mr. Kinnard when this request for acceleration has been granted.

  	Very truly yours,

  	ACASTI PHARMA INC.

  	By: /s/ Prashant Kohli

  	Name: Prashant Kohli

  	Title: 	Chief Executive Officer

   MACROBUTTON DocID \\4133-8110-5740  v1

United States securities and exchange commission logo
October 12, 2023
Brian Ford
Interim Chief Financial Officer
Acasti Pharma Inc.
2572 boul. Daniel-Johnson, 2nd Floor
Laval, Québec, Canada H7T 2R3
Re:Acasti Pharma Inc.
Registration Statement on Form S-3
Filed October 6, 2023
File No. 333-274899
Dear Brian Ford:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Brandon Kinnard